4D Molecular Therapeutics (FDMT) to Release Quarterly Earnings on Thursday

4D Molecular Therapeutics (NASDAQ:FDMT) is expected to release its Q1 2026 results after the market closes on Thursday, May 7th. Analysts expect 4D Molecular Therapeutics to post earnings of ($0.97) per share and revenue of $2.5880 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q1 2026 earning report page for the latest details on the call scheduled for Friday, May 15, 2026 at 9:30 AM ET.

4D Molecular Therapeutics (NASDAQ:FDMT) last announced its earnings results on Wednesday, March 18th. The company reported $0.43 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.53) by $0.96. The company had revenue of $85.09 million during the quarter, compared to analysts’ expectations of $30.86 million. 4D Molecular Therapeutics had a negative net margin of 164.43% and a negative return on equity of 31.75%. On average, analysts expect 4D Molecular Therapeutics to post $-4 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

4D Molecular Therapeutics Stock Up 2.3%

Shares of 4D Molecular Therapeutics stock traded up $0.21 during trading on Tuesday, reaching $9.65. The company’s stock had a trading volume of 350,480 shares, compared to its average volume of 756,275. The business’s 50-day moving average price is $9.35 and its 200-day moving average price is $9.49. The firm has a market cap of $504.71 million, a PE ratio of -3.99 and a beta of 2.77. 4D Molecular Therapeutics has a 52 week low of $3.00 and a 52 week high of $12.34.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on FDMT. Jefferies Financial Group reissued a “buy” rating and issued a $21.00 target price (down from $40.00) on shares of 4D Molecular Therapeutics in a research report on Monday, March 30th. Wall Street Zen raised shares of 4D Molecular Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, March 21st. HC Wainwright reissued a “buy” rating and issued a $36.00 target price on shares of 4D Molecular Therapeutics in a research report on Friday, March 20th. Royal Bank Of Canada boosted their target price on shares of 4D Molecular Therapeutics from $32.00 to $35.00 and gave the company an “outperform” rating in a research report on Thursday, March 19th. Finally, Chardan Capital reaffirmed a “buy” rating and issued a $26.00 price target on shares of 4D Molecular Therapeutics in a research note on Thursday, March 19th. Eight research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $31.25.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Dynamic Technology Lab Private Ltd acquired a new position in 4D Molecular Therapeutics in the first quarter valued at about $39,000. Wexford Capital LP acquired a new position in 4D Molecular Therapeutics in the third quarter valued at about $41,000. AQR Capital Management LLC acquired a new position in 4D Molecular Therapeutics in the first quarter valued at about $46,000. Rangeley Capital LLC acquired a new position in 4D Molecular Therapeutics during the second quarter worth about $48,000. Finally, Daiwa Securities Group Inc. raised its stake in 4D Molecular Therapeutics by 3,362.0% during the fourth quarter. Daiwa Securities Group Inc. now owns 6,370 shares of the company’s stock worth $48,000 after acquiring an additional 6,186 shares in the last quarter. Institutional investors and hedge funds own 99.27% of the company’s stock.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.